TARRIFF SCOTT (CEO) received a stock award from EAGLE PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/29/2024ACC: 0000950170-24-023198
DirectorOfficer· CEO
Since Jun 2018
+9.80K
Net shares
Net buyer
$20.3K
Total sold
0
Open market trades
0B · 0S
2
Total transactions
12.95K acquired · 3.15K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+12.95K
Price / share
—
Trade value
—
% of position
2.9%
2/27/2024
452.94K→465.89K
Common Stock
Direct
Shares
−3.15K
Price / share
$6.44
Trade value
$20.31K
% of position
0.7%
2/27/2024
465.89K→462.74K
Total
Net shares
+9.80K
Net value
-$20.31K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/27/2024 | A · Award | +12.95K | — | — | 2.9% | 452.94K | 465.89K |
| Common Stock Direct | 2/27/2024 | F · Tax Withholding | −3.15K | $6.44 | $20.31K | 0.7% | 465.89K | 462.74K |
| Total | +9.80K | -$20.31K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned992.62K
Total
992.62K indirect992.62K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 992.62K | Indirect |
| Total | 992.62K | 992.62K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported